Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Two key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and pharmacological immunosuppression with insufficient efficacy of GVHD prevention. Modern graft engineering technologies make it possible to create a graft with a balanced cell composition, reducing the risk of adverse events, in particular, severe forms of acute and chronic GVHD, while preserving the immunological function of the graft. In the proposed concept, enrichment of the T graft with regulatory cells will reduce the risk of

Trial Details

NCT ID
NCT07366801
Phase
PHASE2 / PHASE3
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Cyclosporine A (CsA)
  • Sirolimus
  • Ruxolitinib (JAKAVI®)
  • Abatacept
Locations (sample)
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • Informed consent signed by the patient (age 14 to 25 years) and/or his/her legal representative (age 0 to 18 years).
  • The patient has an indication for allogeneic hematopoietic stem cell transplantation (HSCT) established in accordance with the current regulatory f…
  • Planned HSCT from a haploidentical donor
  • The Karnofsky or Lansky score is more than 70%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →